Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 287 articles:
HTML format
Text format



Single Articles


    October 2018
  1. ZHANG J, Zhang Y, Zhang M, Liu C, et al
    FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia.
    Blood. 2018 Oct 3. pii: blood-2018-04-845628. doi: 10.1182/blood-2018-04-845628.
    PubMed     Text format    


  2. HERRMANN M, Krupka C, Deiser K, Brauchle B, et al
    Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Blood. 2018 Oct 1. pii: blood-2018-05-849802. doi: 10.1182/blood-2018-05-849802.
    PubMed     Text format     Abstract available


    September 2018
  3. CHEN LS, Bose P, Cruz ND, Jiang Y, et al
    A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Blood. 2018 Sep 25. pii: blood-2018-06-860593. doi: 10.1182/blood-2018-06-860593
    PubMed     Text format     Abstract available


  4. BALATTI V, Tomasello L, Rassenti LZ, Veneziano D, et al
    MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
    Blood. 2018 Sep 21. pii: blood-2018-04-845115. doi: 10.1182/blood-2018-04-845115
    PubMed     Text format     Abstract available


  5. BOSMA M, Bartels M
    Hairy cell leukemia in a child?!
    Blood. 2018;132:1216.
    PubMed     Text format    


  6. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.
    PubMed     Text format    


  7. BRETONES G, Alvarez MG, Arango JR, Rodriguez D, et al
    Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.
    Blood. 2018 Sep 4. pii: blood-2017-09-804401. doi: 10.1182/blood-2017-09-804401.
    PubMed     Text format     Abstract available


    August 2018
  8. ALSADEQ A, Lenk L, Vadakumchery A, Cousins A, et al
    IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Aug 28. pii: blood-2018-04-844209. doi: 10.1182/blood-2018-04-844209
    PubMed     Text format    


  9. MEDEIROS BC
    Non-zero-sum game of transfusions: EOL in leukemia.
    Blood. 2018;132:676-678.
    PubMed     Text format    


  10. ROGERS KA, Huang Y, Ruppert AS, Awan FT, et al
    Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Blood. 2018 Aug 15. pii: blood-2018-05-853564. doi: 10.1182/blood-2018-05-853564
    PubMed     Text format     Abstract available


  11. KIM T, Moon JH, Ahn JS, Kim YK, et al
    Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia.
    Blood. 2018 Aug 14. pii: blood-2018-04-848028. doi: 10.1182/blood-2018-04-848028
    PubMed     Text format     Abstract available


    July 2018
  12. PIKMAN Y, Stegmaier K
    Targeted therapy for fusion-driven high-risk acute leukemia.
    Blood. 2018 Jul 26. pii: blood-2018-04-784157. doi: 10.1182/blood-2018-04-784157
    PubMed     Text format     Abstract available


  13. RICHARDSON AI, Li W
    Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia.
    Blood. 2018;132:457.
    PubMed     Text format    


  14. LI W, Chastain K
    NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia.
    Blood. 2018;132:456.
    PubMed     Text format    



  15. Ambiguous lineage leukemia treatment.
    Blood. 2018;132:343.
    PubMed     Text format    


  16. DREGER P, Ghia P, Schetelig J, van Gelder M, et al
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
    Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008
    PubMed     Text format     Abstract available


  17. SUD A, Chattopadhyay S, Thomsen H, Sundquist K, et al
    Familial risks of primary myeloid leukemia, myelodysplasia and myeloproliferative neoplasms.
    Blood. 2018 Jul 10. pii: blood-2018-06-858597. doi: 10.1182/blood-2018-06-858597
    PubMed     Text format    


  18. THAKRAL B, Wang SA
    T-cell prolymphocytic leukemia negative for surface CD3 and CD45.
    Blood. 2018;132:111.
    PubMed     Text format    


    June 2018
  19. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991
    PubMed     Text format    


  20. O'DWYER K, Freyer DR, Horan JT
    Treatment strategies for adolescent and young adult patients with acute myeloid leukemia.
    Blood. 2018 Jun 12. pii: blood-2017-12-778472. doi: 10.1182/blood-2017-12-778472
    PubMed     Text format     Abstract available


  21. BOISSEL N, Baruchel A
    Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
    Blood. 2018 Jun 12. pii: blood-2018-02-778530. doi: 10.1182/blood-2018-02-778530
    PubMed     Text format     Abstract available


  22. ROBERTS KG, Janke LJ, Zhao Y, Seth A, et al
    ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
    Blood. 2018 Jun 7. pii: blood-2018-05-849554. doi: 10.1182/blood-2018-05-849554.
    PubMed     Text format    


    May 2018
  23. ALDOSS I, Song JY
    Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.
    Blood. 2018;131:2507.
    PubMed     Text format    


  24. LEBLANC TW, Egan PC, Olszewski AJ
    Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.
    Blood. 2018 May 30. pii: blood-2018-03-842575. doi: 10.1182/blood-2018-03-842575
    PubMed     Text format     Abstract available


  25. MELO-CARDENAS J, Xu Y, Wei J, Tan C, et al
    USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism.
    Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760
    PubMed     Text format     Abstract available


  26. PATEL SS, Dorfman DM
    Leukemic-phase progression of aleukemic mast cell leukemia.
    Blood. 2018;131:2406.
    PubMed     Text format    


  27. TESTI AM, Pession A, Diverio D, Grimwade D, et al
    Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.
    Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528
    PubMed     Text format     Abstract available


  28. MAIFREDE S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895. doi: 10.1182/blood-2018-02-834895
    PubMed     Text format     Abstract available


  29. LUO H, Wang F, Zha J, Li H, et al
    CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
    Blood. 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319
    PubMed     Text format     Abstract available


  30. OLAIYA OO, Li W
    Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia.
    Blood. 2018;131:2178.
    PubMed     Text format    


  31. ROBINSON HR, Qi J, Cook EM, Nichols C, et al
    A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Blood. 2018 May 9. pii: blood-2018-02-830992. doi: 10.1182/blood-2018-02-830992.
    PubMed     Text format     Abstract available


  32. TOPP MS, Zimmerman Z, Cannell P, Dombret H, et al
    Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Blood. 2018 May 8. pii: blood-2017-09-804658. doi: 10.1182/blood-2017-09-804658.
    PubMed     Text format     Abstract available


  33. ZHU HH, Liu YR
    Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia.
    Blood. 2018 May 4. pii: blood-2018-02-834051. doi: 10.1182/blood-2018-02-834051.
    PubMed     Text format    


  34. STEIN EM, Garcia-Manero G, Rizzieri DA, Tibes R, et al
    The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Blood. 2018 May 3. pii: blood-2017-12-818948. doi: 10.1182/blood-2017-12-818948.
    PubMed     Text format     Abstract available


  35. HRUSAK O, De Haas V, Stancikova J, Vakrmanova B, et al
    International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
    Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363.
    PubMed     Text format     Abstract available


    April 2018
  36. LI S, Xu J
    Plasma cell leukemia presenting as "lymphocytosis".
    Blood. 2018;131:1994.
    PubMed     Text format    


  37. YANG J, LeBlanc FR, Dighe SA, Hamele CE, et al
    TRAIL mediates and sustains constitutive NF-kappaB activation in LGL leukemia.
    Blood. 2018 Apr 26. pii: blood-2017-09-808816. doi: 10.1182/blood-2017-09-808816
    PubMed     Text format     Abstract available


  38. MCKENNA MK, Noothi SK, Alhakeem SS, Oben KZ, et al
    Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    Blood. 2018 Apr 25. pii: blood-2017-10-813931. doi: 10.1182/blood-2017-10-813931
    PubMed     Text format     Abstract available


  39. ITZYKSON R, Duployez N, Fasan A, Decool G, et al
    Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.
    Blood. 2018 Apr 24. pii: blood-2018-03-837781. doi: 10.1182/blood-2018-03-837781
    PubMed     Text format     Abstract available


  40. HASAN MK, Yu J, Widhopf GF 2nd, Rassenti LZ, et al
    Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Blood. 2018 Apr 20. pii: blood-2017-12-819383. doi: 10.1182/blood-2017-12-819383
    PubMed     Text format     Abstract available


  41. KLEINSTERN G, Camp NJ, Goldin LR, Vachon CM, et al
    Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
    Blood. 2018 Apr 19. pii: blood-2017-11-814608. doi: 10.1182/blood-2017-11-814608
    PubMed     Text format     Abstract available


  42. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Text format     Abstract available


  43. RANK CU, Toft N, Tuckuviene R, Grell K, et al
    Thromboembolism in Acute Lymphoblastic Leukemia: Results of NOPHO ALL2008 Protocol Treatment in Patients 1-45 Years.
    Blood. 2018 Apr 16. pii: blood-2018-01-827949. doi: 10.1182/blood-2018-01-827949
    PubMed     Text format     Abstract available


  44. WANG F, Demir S, Gehringer F, Osswald CD, et al
    Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
    PubMed     Text format     Abstract available


  45. STATLER A, Othus M, Erba HP, Chauncey TR, et al
    Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
    Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
    PubMed     Text format     Abstract available


    March 2018
  46. CORTES JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, et al
    Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086
    PubMed     Text format     Abstract available


  47. RUIZ S, Chen YH
    Acute myeloid leukemia with coexistence of t(9;22) and inv(16).
    Blood. 2018;131:1263.
    PubMed     Text format    


  48. HALLEK M, Cheson BD, Catovsky D, Caligaris-Cappio F, et al
    Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
    Blood. 2018 Mar 14. pii: blood-2017-09-806398. doi: 10.1182/blood-2017-09-806398
    PubMed     Text format     Abstract available


  49. YAMATO G, Shiba N, Yoshida K, Hara Y, et al
    RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
    Blood. 2018 Mar 14. pii: blood-2017-11-814442. doi: 10.1182/blood-2017-11-814442
    PubMed     Text format    


  50. SHOMALI W, Gotlib J
    Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
    Blood. 2018;131:1036.
    PubMed     Text format    


    February 2018
  51. KREITMAN RJ, Tallman MS, Robak T, Coutre S, et al
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
    Blood. 2018 Feb 27. pii: blood-2017-09-803072. doi: 10.1182/blood-2017-09-803072
    PubMed     Text format     Abstract available


  52. DUARTE D, Hawkins ED, Lo Celso C
    The interplay of leukemia cells and the bone marrow microenvironment.
    Blood. 2018 Feb 27. pii: blood-2017-12-784132. doi: 10.1182/blood-2017-12-784132
    PubMed     Text format     Abstract available


  53. LIU T, Wen L, Yuan H, Wang Y, et al
    Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Blood. 2018 Feb 27. pii: blood-2017-11-818716. doi: 10.1182/blood-2017-11-818716
    PubMed     Text format    


  54. SCHLIFFKE S, Buhs S, Bolz S, Gerull H, et al
    The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
    Blood. 2018 Feb 23. pii: blood-2017-06-788166. doi: 10.1182/blood-2017-06-788166
    PubMed     Text format    


  55. JAITLY V, Wang W
    B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
    Blood. 2018;131:941.
    PubMed     Text format    


  56. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.
    PubMed     Text format    


  57. GALLIPOLI P, Giotopoulos G, Tzelepis K, Costa ASH, et al
    Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
    Blood. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035
    PubMed     Text format     Abstract available


  58. WIERZ M, Pierson S, Guyonnet L, Viry E, et al
    Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
    Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267
    PubMed     Text format    


  59. BHAGWAT AS, Lu B, Vakoc CR
    Enhancer dysfunction in leukemia.
    Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
    PubMed     Text format     Abstract available


  60. ZHANG Y, Gao Y, Zhang H, Zhang J, et al
    PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
    Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
    PubMed     Text format     Abstract available


  61. YUN S, Zhang L, Patel MR, Knepper TC, et al
    Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
    Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.
    PubMed     Text format    


  62. MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
    Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
    PubMed     Text format     Abstract available


  63. O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
    Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
    Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
    PubMed     Text format     Abstract available


    January 2018
  64. DINMOHAMED AG, Posthuma EFM, Visser O, Kater AP, et al
    Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands.
    Blood. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381
    PubMed     Text format    


  65. TAKAHASHI K, Hu B, Wang F, Yan Y, et al
    Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
    Blood. 2018 Jan 22. pii: blood-2017-11-817296. doi: 10.1182/blood-2017-11-817296
    PubMed     Text format     Abstract available


  66. GOKBUGET N, Dombret H, Bonifacio M, Reichle A, et al
    Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-798322. doi: 10.1182/blood-2017-08-798322
    PubMed     Text format     Abstract available


  67. HANDGRETINGER R, Schilbach K
    The potential role of gammadelta T cells after allogeneic HCT for leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-752162. doi: 10.1182/blood-2017-08-752162
    PubMed     Text format     Abstract available


  68. GUTJAHR JC, Szenes E, Tschech L, Asslaber D, et al
    Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Blood. 2018 Jan 19. pii: blood-2017-08-802462. doi: 10.1182/blood-2017-08-802462
    PubMed     Text format     Abstract available


  69. SUN W, Triche T Jr., Malvar J, Gaynon P, et al
    A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.
    Blood. 2018 Jan 16. pii: blood-2017-09-803809. doi: 10.1182/blood-2017-09-803809
    PubMed     Text format     Abstract available


  70. JANOVSKA P, Verner J, Kohoutek J, Bryjova L, et al
    Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.
    Blood. 2018 Jan 9. pii: blood-2017-05-786947. doi: 10.1182/blood-2017-05-786947.
    PubMed     Text format     Abstract available


  71. BRIDE KL, Vincent TL, Im SY, Aplenc R, et al
    Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).
    Blood. 2018 Jan 5. pii: blood-2017-07-794214. doi: 10.1182/blood-2017-07-794214.
    PubMed     Text format     Abstract available


  72. COUTRE S, Choi M, Furman RR, Eradat H, et al
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Blood. 2018 Jan 5. pii: blood-2017-06-788133. doi: 10.1182/blood-2017-06-788133.
    PubMed     Text format     Abstract available


  73. LOCKE FL, Anasetti C
    Off-the-shelf TCR for graft-versus-leukemia without GVHD.
    Blood. 2018;131:5-7.
    PubMed     Text format    


  74. MILNE TA
    LEDGF: a leukemia-specific target.
    Blood. 2018;131:4-5.
    PubMed     Text format    


  75. AULETTA JJ
    AML: exposed and exploited?
    Blood. 2018;131:8-10.
    PubMed     Text format    


  76. EL ASHKAR S, Schwaller J, Pieters T, Goossens S, et al
    LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
    Blood. 2018;131:95-107.
    PubMed     Text format     Abstract available


  77. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Text format     Abstract available


    December 2017
  78. GROCKOWIAK E, Laperrousaz B, Jeanpierre S, Voeltzel T, et al
    Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
    Blood. 2017;130:2860-2871.
    PubMed     Text format     Abstract available


  79. SHIOZAWA Y, Malcovati L, Galli A, Pellagatti A, et al
    Gene expression and risk of leukemic transformation in myelodysplasia.
    Blood. 2017;130:2642-2653.
    PubMed     Text format     Abstract available


  80. PRATS-MARTIN C, Morales-Camacho RM
    Circulating hypergranular neoplastic cells: not always leukemic promyelocytes.
    Blood. 2017;130:2689.
    PubMed     Text format    


  81. YAO L, Wen L, Wang N, Liu T, et al
    Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA.
    Blood. 2017 Dec 13. pii: blood-2017-09-807370. doi: 10.1182/blood-2017-09-807370
    PubMed     Text format    


  82. RAIKAR SS, Park SI, Leong T, Jaye DL, et al
    Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
    Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.
    PubMed     Text format    


  83. WEI AH, Tiong IS
    Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Blood. 2017;130:2469-2474.
    PubMed     Text format     Abstract available


  84. BOSE P, Konopleva MY
    T-PLL: another check on the venetoclax list?
    Blood. 2017;130:2447-2448.
    PubMed     Text format    


  85. OBSTFELD AE, Frey NV, Mansfield K, Lacey SF, et al
    Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
    Blood. 2017;130:2569-2572.
    PubMed     Text format    


  86. STEIN EM, Walter RB, Erba HP, Fathi AT, et al
    A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML).
    Blood. 2017 Dec 1. pii: blood-2017-06-789800. doi: 10.1182/blood-2017-06-789800.
    PubMed     Text format     Abstract available


    November 2017
  87. COOPER JN, Young NS
    Clonality in context: hematopoietic clones in their marrow environment.
    Blood. 2017;130:2363-2372.
    PubMed     Text format     Abstract available


  88. ZHEN T, Kwon EM, Zhao L, Hsu J, et al
    Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.
    Blood. 2017;130:2431-2442.
    PubMed     Text format     Abstract available


  89. RASHIDI A, Gilles S
    The unused iron.
    Blood. 2017;130:2445.
    PubMed     Text format    


  90. STRAUBE J, Ling VY, Hill GR, Lane SW, et al
    The impact of age, NPM1(mut) and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia.
    Blood. 2017 Nov 28. pii: blood-2017-09-807438. doi: 10.1182/blood-2017-09-807438
    PubMed     Text format    


  91. JOHNSRUD AJ, Pina-Oviedo S
    Carcinocythemia (carcinoma cell leukemia).
    Blood. 2017;130:2357.
    PubMed     Text format    


  92. CHAI-ADISAKSOPHA C, Brown JR
    FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
    Blood. 2017;130:2278-2282.
    PubMed     Text format     Abstract available


  93. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  94. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  95. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  96. HU Z, Konoplev S
    Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia.
    Blood. 2017;130:2150.
    PubMed     Text format    


  97. ISSA GC, Kantarjian HM, Gonzalez GN, Borthakur G, et al
    Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
    Blood. 2017;130:2084-2091.
    PubMed     Text format     Abstract available


  98. HEHLMANN R
    Prognostic relevance of CCAs/Ph(-) in CML settled.
    Blood. 2017;130:2046-2047.
    PubMed     Text format    


  99. LOCATELLI F, Valsecchi MG, Moricke A, Zimmermann M, et al
    Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
    Blood. 2017;130:2146-2149.
    PubMed     Text format    


  100. SERAFIN V, Capuzzo G, Milani G, Minuzzo SA, et al
    Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2017 Nov 3. pii: blood-2017-05-784603. doi: 10.1182/blood-2017-05-784603.
    PubMed     Text format     Abstract available


  101. TAWARA I, Kageyama S, Miyahara Y, Fujiwara H, et al
    Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
    Blood. 2017;130:1985-1994.
    PubMed     Text format     Abstract available


    October 2017
  102. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI): a systematic review and meta-analysis.
    Blood. 2017 Oct 30. pii: blood-2017-09-806034. doi: 10.1182/blood-2017-09-806034
    PubMed     Text format    


  103. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  104. FALINI B, Sportoletti P
    A scale of "bad" co-mutations in NPM1-driven AML.
    Blood. 2017;130:1877-1879.
    PubMed     Text format    


  105. BOUVIER S, Martin M
    Atypical monoblasts with micronuclei.
    Blood. 2017;130:1958.
    PubMed     Text format    


  106. GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
    AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
    Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
    PubMed     Text format     Abstract available


  107. DOSSA RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, et al
    Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
    Blood. 2017 Oct 19. pii: blood-2017-07-791608. doi: 10.1182/blood-2017-07-791608
    PubMed     Text format     Abstract available


  108. PETIT A, Trinquand A, Chevret S, Ballerini P, et al
    Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-04-778829. doi: 10.1182/blood-2017-04-778829
    PubMed     Text format     Abstract available


  109. TIAO G, Improgo MR, Tausch E, Fernandes SM, et al
    Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128
    PubMed     Text format    


  110. HARANKHEDKAR S, Gupta R
    MPO-negative inclusions and Auer rod-like structures in a case of acute myeloid leukemia with t(8;21).
    Blood. 2017;130:1869.
    PubMed     Text format    


  111. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  112. ODA SK, Daman AW, Garcia NM, Wagener F, et al
    A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.
    Blood. 2017 Oct 17. pii: blood-2017-04-777052. doi: 10.1182/blood-2017-04-777052
    PubMed     Text format     Abstract available


  113. SANDA T
    RUNX1 in T-ALL: tumor suppressive or oncogenic?
    Blood. 2017;130:1686-1688.
    PubMed     Text format    


  114. XU Z
    AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis.
    Blood. 2017;130:1775.
    PubMed     Text format    


  115. APPELBAUM FR, Bernstein ID
    Gemtuzumab ozogamicin for acute myeloid leukemia.
    Blood. 2017 Oct 11. pii: blood-2017-09-797712. doi: 10.1182/blood-2017-09-797712
    PubMed     Text format     Abstract available


  116. MAR BG, Chu SH, Kahn JD, Krivstov AV, et al
    SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
    Blood. 2017 Oct 10. pii: blood-2017-03-775569. doi: 10.1182/blood-2017-03-775569
    PubMed     Text format     Abstract available


  117. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017;130:1620-1627.
    PubMed     Text format     Abstract available


  118. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  119. MARLEIN CR, Zaitseva L, Piddock RE, Robinson SD, et al
    NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.
    Blood. 2017;130:1649-1660.
    PubMed     Text format     Abstract available


  120. WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
    PubMed     Text format     Abstract available


  121. TASIAN SK, Loh ML, Hunger SP
    Philadelphia chromosome-like acute lymphoblastic leukemia.
    Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
    PubMed     Text format     Abstract available


    September 2017
  122. THAKRAL B, Wang SA
    "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood. 2017;130:1600.
    PubMed     Text format    


  123. KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
    Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Blood. 2017;130:1585-1596.
    PubMed     Text format     Abstract available


  124. JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
    Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Blood. 2017;130:1514-1522.
    PubMed     Text format     Abstract available


  125. ADVANI AS
    "MOR" engineering of antibodies in ALL.
    Blood. 2017;130:1487-1488.
    PubMed     Text format    


  126. BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
    First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
    PubMed     Text format     Abstract available


  127. MUELLER KT, Maude SL, Porter DL, Frey N, et al
    Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
    PubMed     Text format     Abstract available


  128. SHEA TC
    Are outcomes of allografts for CLL still relevant?
    Blood. 2017;130:1393-1394.
    PubMed     Text format    


  129. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  130. KRAMER I, Stilgenbauer S, Dietrich S, Bottcher S, et al
    Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
    Blood. 2017;130:1477-1480.
    PubMed     Text format    


  131. ZURLI V, Wimmer G, Cattaneo F, Candi V, et al
    Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
    Blood. 2017 Sep 20. pii: blood-2017-03-775858. doi: 10.1182/blood-2017-03-775858
    PubMed     Text format     Abstract available


  132. WANG HY, Feldman AL
    Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia.
    Blood. 2017;130:1387.
    PubMed     Text format    


  133. LIN S, Ptasinska A, Chen X, Shrestha M, et al
    A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Blood. 2017;130:1213-1222.
    PubMed     Text format     Abstract available


  134. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  135. AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
    A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
    Blood. 2017;130:1270-1273.
    PubMed     Text format    


    August 2017
  136. BAZARBACHI A
    CDK9 inhibition for ATL therapy.
    Blood. 2017;130:1074-1075.
    PubMed     Text format    


  137. LEHNERTZ B, Zhang YW, Boivin I, Mayotte N, et al
    H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.
    Blood. 2017 Aug 30. pii: blood-2017-03-774653. doi: 10.1182/blood-2017-03-774653
    PubMed     Text format     Abstract available


  138. DOVEY OM, Cooper JL, Mupo A, Grove CS, et al
    Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.
    Blood. 2017 Aug 23. pii: blood-2017-01-760595. doi: 10.1182/blood-2017-01-760595
    PubMed     Text format     Abstract available


  139. BRUNSON A, Keegan THM, Bang H, Mahajan A, et al
    Increased risk of leukemia among sickle cell disease patients in California.
    Blood. 2017 Aug 22. pii: blood-2017-05-783233. doi: 10.1182/blood-2017-05-783233
    PubMed     Text format    


  140. ANGUILLE S, Van de Velde AL, Smits EL, Van Tendeloo VF, et al
    Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia.
    Blood. 2017 Aug 22. pii: blood-2017-04-780155. doi: 10.1182/blood-2017-04-780155
    PubMed     Text format     Abstract available


  141. NAGEL I, Bartels M, Duell J, Oberg HH, et al
    Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.
    Blood. 2017 Aug 21. pii: blood-2017-05-782888. doi: 10.1182/blood-2017-05-782888
    PubMed     Text format     Abstract available


  142. ZHOU XY, Behdad A
    Relapse of an acute leukemia of mixed lineage as an isolated orbital mass.
    Blood. 2017;130:953.
    PubMed     Text format    


  143. KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
    GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Blood. 2017;130:908-919.
    PubMed     Text format     Abstract available


  144. MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
    Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Blood. 2017;130:946-948.
    PubMed     Text format    


  145. DURHAM BH, Getta B, Dietrich S, Taylor J, et al
    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
    Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
    PubMed     Text format     Abstract available


  146. KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
    JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Blood. 2017;130:789-802.
    PubMed     Text format     Abstract available


  147. WOUTERS BJ
    Hitting the target in IDH2 mutant AML.
    Blood. 2017;130:693-694.
    PubMed     Text format    


  148. SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
    Blood. 2017;130:832-835.
    PubMed     Text format    


  149. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017 Aug 9. pii: blood-2017-02-749101. doi: 10.1182/blood-2017-02-749101.
    PubMed     Text format     Abstract available


  150. CHOI A, Illendula A, Pulikkan JA, Roderick JE, et al
    RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-03-775536. doi: 10.1182/blood-2017-03-775536.
    PubMed     Text format     Abstract available


  151. LAFAGE-POCHITALOFF M, Baranger L, Hunault M, Cuccuini W, et al
    Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-05-783852. doi: 10.1182/blood-2017-05-783852.
    PubMed     Text format     Abstract available


  152. MIZUKAWA B, O'Brien E, Moreira DC, Wunderlich M, et al
    Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
    Blood. 2017 Aug 4. pii: blood-2016-12-758458. doi: 10.1182/blood-2016-12-758458.
    PubMed     Text format     Abstract available


  153. LILLJEBJORN H, Fioretos T
    New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 4. pii: blood-2017-05-742643. doi: 10.1182/blood-2017-05-742643.
    PubMed     Text format     Abstract available


  154. ARRANTO C, Tzankov A
    Broken heart by T-prolymphocytic leukemia.
    Blood. 2017;130:691.
    PubMed     Text format    


  155. IZRAELI S, Eckert C
    Targeted therapy of CNS leukemia?
    Blood. 2017;130:562-563.
    PubMed     Text format    


  156. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  157. WALLACE JA, O'Connell RM
    MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
    Blood. 2017 Jul 27. pii: blood-2016-10-697698. doi: 10.1182/blood-2016-10-697698
    PubMed     Text format     Abstract available


  158. GODLEY LA, Shimamura A
    Genetic predisposition to hematologic malignancies: management and surveillance.
    Blood. 2017;130:424-432.
    PubMed     Text format     Abstract available


  159. YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Blood. 2017;130:397-407.
    PubMed     Text format     Abstract available


  160. RAU RE
    CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3.
    Blood. 2017;130:385-386.
    PubMed     Text format    


  161. DONG L, Zheng H, Qu CK
    CCL3 is a key mediator for the leukemogenic effect of Ptpn11 activating mutations in the stem cell microenvironment.
    Blood. 2017 Jul 27. pii: blood-2017-06-791103. doi: 10.1182/blood-2017-06-791103
    PubMed     Text format    


  162. TOBOSO DG, Campos CB
    Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32).
    Blood. 2017;130:380.
    PubMed     Text format    


  163. GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Blood. 2017;130:285-296.
    PubMed     Text format     Abstract available


  164. AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
    CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Blood. 2017;130:297-309.
    PubMed     Text format     Abstract available



  165. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood. 2017;130:232.
    PubMed     Text format    


  166. THAKRAL B, Muzzafar T
    Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Blood. 2017;130:231.
    PubMed     Text format    


  167. TALSMA CE, Boyer DF
    Myeloid leukemia associated with Down syndrome.
    Blood. 2017;130:230.
    PubMed     Text format    


  168. AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
    USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood. 2017;130:156-166.
    PubMed     Text format     Abstract available


  169. SAMPATH D
    Targeting deubiquitinases in CLL.
    Blood. 2017;130:100-101.
    PubMed     Text format    


  170. PILLAI V, Maude SL
    CART attack.
    Blood. 2017;130:229.
    PubMed     Text format    


  171. SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
    An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
    Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
    PubMed     Text format     Abstract available


  172. CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
    Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
    Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121
    PubMed     Text format    


  173. BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
    Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
    Blood. 2017;130:86-88.
    PubMed     Text format    


  174. KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
    HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
    Blood. 2017;130:84-86.
    PubMed     Text format    


    June 2017
  175. QUESADA AE, Kanagal-Shamanna R
    Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
    Blood. 2017;129:3503.
    PubMed     Text format    


  176. LEVIS M
    Midostaurin approved for FLT3-mutated AML.
    Blood. 2017;129:3403-3406.
    PubMed     Text format     Abstract available


  177. CHAUDHRY P, Singh M, Triche TJ, Guzman M, et al
    GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
    Blood. 2017;129:3465-3475.
    PubMed     Text format     Abstract available


  178. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  179. RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
    In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
    Blood. 2017;129:3495-3498.
    PubMed     Text format    


  180. MORIYAMA T, Yang YL, Nishii R, Ariffin H, et al
    Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
    Blood. 2017 Jun 28. pii: blood-2017-05-782383. doi: 10.1182/blood-2017-05-782383
    PubMed     Text format     Abstract available


  181. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  182. BRIERLEY CK, Eyre TA
    Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
    Blood. 2017;129:3396.
    PubMed     Text format    


  183. ANDERSON MA, Tam C, Lew TE, Juneja S, et al
    Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
    Blood. 2017;129:3362-3370.
    PubMed     Text format     Abstract available


  184. MALCOVATI L, Galli A, Travaglino E, Ambaglio I, et al
    Clinical significance of somatic mutation in unexplained blood cytopenia.
    Blood. 2017;129:3371-3378.
    PubMed     Text format     Abstract available


  185. RESHMI SC, Harvey RC, Roberts KG, Stonerock E, et al
    Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Blood. 2017;129:3352-3361.
    PubMed     Text format     Abstract available


  186. TOMIZAWA D, Kolb EA
    Down syndrome and AML: where do we go from here?
    Blood. 2017;129:3274-3275.
    PubMed     Text format    


  187. SHAND JC
    Looking up for AML in Down syndrome.
    Blood. 2017;129:3273-3274.
    PubMed     Text format    


  188. GRIBBEN JG
    Restoring leukemia cell function from the inside out.
    Blood. 2017;129:3137-3138.
    PubMed     Text format    


  189. GOOSSENS S, Van Vlierberghe P
    Novel oncogenic noncoding mutations in T-ALL.
    Blood. 2017;129:3140-3142.
    PubMed     Text format    


  190. GARRISON BS, Rybak AP, Beerman I, Heesters B, et al
    ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
    Blood. 2017 Jun 14. pii: blood-2016-09-738591. doi: 10.1182/blood-2016-09-738591
    PubMed     Text format     Abstract available


  191. PROKOCIMER M, Molchadsky A, Rotter V
    Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy.
    Blood. 2017 Jun 12. pii: blood-2017-02-763086. doi: 10.1182/blood-2017-02-763086
    PubMed     Text format     Abstract available


  192. PRIETO D, Sotelo N, Seija N, Sernbo S, et al
    S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-kappaB activity during disease progression.
    Blood. 2017 Jun 8. pii: blood-2017-02-769851. doi: 10.1182/blood-2017-02-769851.
    PubMed     Text format     Abstract available


  193. WALLACE JA, Kagele DA, Eiring AM, Kim CN, et al
    miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Blood. 2017;129:3074-3086.
    PubMed     Text format     Abstract available


  194. RASHIDI A, Courville EL
    Double-heart sign.
    Blood. 2017;129:3134.
    PubMed     Text format    


  195. KATO I, Nishinaka Y, Nakamura M, Akarca AU, et al
    Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.
    Blood. 2017;129:3126-3129.
    PubMed     Text format    


  196. STEIN EM, DiNardo CD, Pollyea DA, Fathi AT, et al
    Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.
    Blood. 2017 Jun 6. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.
    PubMed     Text format     Abstract available


  197. AMATANGELO MD, Quek L, Shih A, Stein EM, et al
    Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Blood. 2017 Jun 6. pii: blood-2017-04-779447. doi: 10.1182/blood-2017-04-779447.
    PubMed     Text format     Abstract available


  198. LOCATELLI F, Merli P, Pagliara D, Li Pira G, et al
    Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion.
    Blood. 2017 Jun 6. pii: blood-2017-04-779769. doi: 10.1182/blood-2017-04-779769.
    PubMed     Text format     Abstract available


  199. CHELONI G, Tanturli M, Tusa I, DeSouza NH, et al
    Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
    Blood. 2017 Jun 2. pii: blood-2016-10-745588. doi: 10.1182/blood-2016-10-745588.
    PubMed     Text format     Abstract available


  200. SOLARY E, Itzykson R
    How I treat chronic myelomonocytic leukemia.
    Blood. 2017 Jun 1. pii: blood-2017-04-736421. doi: 10.1182/blood-2017-04-736421.
    PubMed     Text format     Abstract available


    May 2017
  201. MUNCH V, Trentin L, Herzig J, Demir S, et al
    Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor.
    Blood. 2017 May 26. pii: blood-2017-03-769315. doi: 10.1182/blood-2017-03-769315
    PubMed     Text format     Abstract available


  202. MAN N, Tan Y, Sun XJ, Liu F, et al
    Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
    Blood. 2017;129:2782-2792.
    PubMed     Text format     Abstract available


  203. HOVORKOVA L, Zaliova M, Venn NC, Bleckmann K, et al
    Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
    Blood. 2017;129:2771-2781.
    PubMed     Text format     Abstract available


  204. HUNGER SP
    CML in blast crisis: more common than we think?
    Blood. 2017;129:2713-2714.
    PubMed     Text format    


  205. WALTER HS, Jayne S, Rule SA, Cartron G, et al
    Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
    Blood. 2017;129:2808-2810.
    PubMed     Text format    


  206. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  207. CHEN TL, Tran M, Lakshmanan A, Harrington BK, et al
    NF-kappaB p50 (nfkb1) contributes to pathogenesis in the Emu-TCL1 mouse model of chronic lymphocytic leukemia.
    Blood. 2017 May 17. pii: blood-2017-01-761130. doi: 10.1182/blood-2017-01-761130
    PubMed     Text format    


  208. BARR PM, Brown JR, Hillmen P, O'Brien S, et al
    Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood. 2017;129:2612-2615.
    PubMed     Text format     Abstract available


  209. VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
    Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Blood. 2017;129:2636-2644.
    PubMed     Text format     Abstract available


  210. LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
    Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
    Blood. 2017;129:2657-2666.
    PubMed     Text format     Abstract available


  211. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  212. PINTON P
    A mitochondrial drug to treat AML.
    Blood. 2017;129:2597-2599.
    PubMed     Text format    


  213. SMITH CC, Paguirigan A, Jeschke GR, Lin KC, et al
    Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis.
    Blood. 2017 May 10. pii: blood-2016-04-711820. doi: 10.1182/blood-2016-04-711820
    PubMed     Text format     Abstract available


  214. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  215. DOURADO KMC, Baik J, Oliveira VKP, Beltrame M, et al
    Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
    Blood. 2017;129:2526-2536.
    PubMed     Text format     Abstract available


  216. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  217. LAMPSON BL, Yu L, Glynn RJ, Barrientos JC, et al
    Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Blood. 2017;129:2581-2584.
    PubMed     Text format    


  218. GORINI F, Azzimonti L, Delfanti G, Scarfo L, et al
    Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
    Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
    PubMed     Text format     Abstract available


    April 2017
  219. PARILLA M, Venkataraman G
    The thin line between CML and CMML.
    Blood. 2017;129:2456.
    PubMed     Text format    


  220. RADICH J
    Understanding CML, 1 cell at a time.
    Blood. 2017;129:2339-2340.
    PubMed     Text format    


  221. KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
    Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
    PubMed     Text format     Abstract available


  222. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  223. VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
    Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
    PubMed     Text format     Abstract available


  224. GARDNER RA, Finney O, Annesley C, Brakke H, et al
    Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
    Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
    PubMed     Text format     Abstract available


  225. HU S, Qian M, Zhang H, Guo Y, et al
    Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
    Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162
    PubMed     Text format    



  226. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
    Blood. 2017;129:2204.
    PubMed     Text format    


  227. PORCHER C, Chagraoui H, Kristiansen MS
    SCL/TAL1: a multifaceted regulator from blood development to disease.
    Blood. 2017;129:2051-2060.
    PubMed     Text format     Abstract available


  228. SOOD R, Kamikubo Y, Liu P
    Role of RUNX1 in hematological malignancies.
    Blood. 2017;129:2070-2082.
    PubMed     Text format     Abstract available


  229. AVELLINO R, Delwel R
    Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation.
    Blood. 2017;129:2083-2091.
    PubMed     Text format     Abstract available


  230. DE BRUIJN M, Dzierzak E
    Runx transcription factors in the development and function of the definitive hematopoietic system.
    Blood. 2017;129:2061-2069.
    PubMed     Text format     Abstract available


  231. UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
    Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
    Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
    PubMed     Text format     Abstract available


  232. BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
    Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
    PubMed     Text format     Abstract available


  233. TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
    Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
    PubMed     Text format     Abstract available


  234. LANDIER W, Chen Y, Hageman L, Kim H, et al
    Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
    Blood. 2017;129:1919-1926.
    PubMed     Text format     Abstract available


  235. DOWSE RT, Ireland RM
    Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL.
    Blood. 2017;129:2038.
    PubMed     Text format    


    March 2017
  236. GO RS, Winters JL, Kay NE
    How I treat autoimmune hemolytic anemia.
    Blood. 2017 Mar 30. pii: blood-2016-11-693689. doi: 10.1182/blood-2016-11-693689
    PubMed     Text format     Abstract available


  237. GREENBERG PL
    The classical nature of distinctive CMML monocytes.
    Blood. 2017;129:1745-1746.
    PubMed     Text format    


  238. FALANGA A
    Predicting APL lethal bleeding in the ATRA era.
    Blood. 2017;129:1739-1740.
    PubMed     Text format    


  239. TALATI C, Zhang L, Shaheen G, Kuykendall A, et al
    Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
    Blood. 2017;129:1881-1883.
    PubMed     Text format    


  240. GEYER MB, Hsu M, Devlin SM, Tallman MS, et al
    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
    Blood. 2017;129:1878-1881.
    PubMed     Text format    


  241. BACHEGOWDA LS, Saliba RM, Ramlal R, Kongtim P, et al
    Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.
    Blood. 2017 Mar 28. pii: blood-2017-02-766154. doi: 10.1182/blood-2017-02-766154
    PubMed     Text format    


  242. GARZON R, Savona M, Baz R, Andreeff M, et al
    A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
    PubMed     Text format     Abstract available


  243. FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973
    PubMed     Text format    


  244. CHENG CK, Wang AZ, Wong TH, Wan TS, et al
    FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
    Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707
    PubMed     Text format    


  245. FRISMANTAS V, Dobay MP, Rinaldi A, Tchinda J, et al
    Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Blood. 2017;129:e26-e37.
    PubMed     Text format     Abstract available


  246. WONG TN, Link DC
    miR-125b promotes leukemogenesis via VEGFA.
    Blood. 2017;129:1409-1410.
    PubMed     Text format    


  247. MERTENS D, Stilgenbauer S
    Ibrutinib-resistant CLL: unwanted and unwonted!
    Blood. 2017;129:1407-1409.
    PubMed     Text format    


  248. SHAFAT MS, Oellerich T, Mohr S, Robinson SD, et al
    Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
    Blood. 2017;129:1320-1332.
    PubMed     Text format     Abstract available


  249. SCHURINGA JJ
    Smart niche usage: release its fat and burn it!
    Blood. 2017;129:1239-1240.
    PubMed     Text format    


  250. DUNCAVAGE EJ, Uy GL, Petti AA, Miller CA, et al
    Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
    Blood. 2017;129:1397-1401.
    PubMed     Text format    


  251. GIRARDI T, Vicente C, Cools J, De Keersmaecker K, et al
    The genetics and molecular biology of T-ALL.
    Blood. 2017;129:1113-1123.
    PubMed     Text format     Abstract available


  252. HUGHES A, Clarson J, Tang C, Vidovic L, et al
    CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Blood. 2017;129:1166-1176.
    PubMed     Text format     Abstract available


  253. KNAPPER S, Russell N, Gilkes A, Hills RK, et al
    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Blood. 2017;129:1143-1154.
    PubMed     Text format     Abstract available


  254. SCHEINBERG DA
    Immune reconstitution and remission in CML.
    Blood. 2017;129:1064-1065.
    PubMed     Text format    


  255. STONE RM
    3 + 7 + FLT3 inhibitors: 1 + 1 not equal 2.
    Blood. 2017;129:1061-1062.
    PubMed     Text format    


  256. ALDOSS I, Song JY
    Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
    Blood. 2017;129:1231.
    PubMed     Text format    


  257. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


  258. LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
    Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
    Blood. 2017;129:1227-1230.
    PubMed     Text format    


    February 2017
  259. AGARWAL P, Zhang B, Ho Y, Cook A, et al
    Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Blood. 2017;129:1008-1020.
    PubMed     Text format     Abstract available


  260. KORN C, Mendez-Ferrer S
    Myeloid malignancies and the microenvironment.
    Blood. 2017;129:811-822.
    PubMed     Text format     Abstract available


  261. LANEUVILLE P
    Stopping second-generation TKIs in CML.
    Blood. 2017;129:805-806.
    PubMed     Text format    


  262. POURABDOLLAH M, Chang H
    Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
    Blood. 2017;129:918.
    PubMed     Text format    


  263. REITER A, Gotlib J
    Myeloid neoplasms with eosinophilia.
    Blood. 2017;129:704-714.
    PubMed     Text format     Abstract available


  264. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


  265. ALSULIMAN A, Muftuoglu M, Khoder A, Ahn YO, et al
    A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
    Blood. 2017;129:740-758.
    PubMed     Text format     Abstract available


  266. LOWENBERG B
    Introduction to the Review Series on Leukemic Stem Cells.
    Blood. 2017 Feb 3. pii: blood-2017-01-753319. doi: 10.1182/blood-2017-01-753319.
    PubMed     Text format    


  267. COMOLI P, Basso S, Riva G, Barozzi P, et al
    BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
    Blood. 2017;129:582-586.
    PubMed     Text format     Abstract available


  268. PRATZ KW, Levis M
    How I treat FLT3-mutated AML.
    Blood. 2017;129:565-571.
    PubMed     Text format     Abstract available


  269. LULLA P, Heslop HE
    Fall of the mutants: T cells targeting BCR-ABL.
    Blood. 2017;129:539-540.
    PubMed     Text format    


    January 2017
  270. DOHNER H, Estey E, Grimwade D, Amadori S, et al
    Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Blood. 2017;129:424-447.
    PubMed     Text format     Abstract available


  271. CHESNAIS V, Arcangeli ML, Delette C, Rousseau A, et al
    Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Blood. 2017;129:484-496.
    PubMed     Text format     Abstract available


  272. WARFVINGE R, Geironson Ulfsson L, Sommarin MN, Lang S, et al
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Blood. 2017 Jan 25. pii: blood-2016-07-728873. doi: 10.1182/blood-2016-07-728873
    PubMed     Text format     Abstract available


  273. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  274. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.
    PubMed     Text format    


  275. VAINCHENKER W, Plo I
    P53 deletion and NrasG12D cooperate for AML.
    Blood. 2017;129:271-273.
    PubMed     Text format    


  276. ASKEW D, Pareek TK, Eid S, Ganguly S, et al
    Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Blood. 2017;129:246-256.
    PubMed     Text format     Abstract available


  277. ABU ZAID M, Wu J, Wu C, Logan BR, et al
    Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
    Blood. 2017;129:162-170.
    PubMed     Text format     Abstract available


  278. TARAFDAR A, Hopcroft LE, Gallipoli P, Pellicano F, et al
    CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
    Blood. 2017;129:199-208.
    PubMed     Text format     Abstract available


  279. NICOLINI FE
    CML stem cells: evasion for better invasion.
    Blood. 2017;129:141-142.
    PubMed     Text format    


  280. LEE LY, Hernandez D, Rajkhowa T, Smith SC, et al
    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
    Blood. 2017;129:257-260.
    PubMed     Text format    


  281. WALTER MJ
    Antecedent CHIP in CML?
    Blood. 2017;129:3-4.
    PubMed     Text format    


    December 2016
  282. STRAMUCCI L, Perrotti D
    Twisting IL-1 signaling to kill CML stem cells.
    Blood. 2016;128:2592-2593.
    PubMed     Text format    


    November 2016
  283. WILLIAMS KM
    How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Blood. 2016 Nov 16. pii: blood-2016-08-693507.
    PubMed     Text format     Abstract available


  284. CUSAN M, Vegi NM, Mulaw MA, Bamezai S, et al
    Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.
    Blood. 2016 Nov 8. pii: blood-2016-04-706978.
    PubMed     Text format     Abstract available


  285. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.
    PubMed     Text format    


    August 2016
  286. COOMBS J, Bera E
    B cells mimicking blasts after an allogeneic stem cell transplantation.
    Blood. 2016;128:881.
    PubMed     Text format    


    February 2016
  287. TEIRA P, Battiwalla M, Ramanathan M, Barrett AJ, et al
    Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis.
    Blood. 2016 Feb 16. pii: blood-2015-11-679639.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: